Physician
Internal Medicine
Dr. Jeffrey A. Zonder, MD
|
|
Give Review
Jeffrey Zonder is an expert in the field of Internal Medicine. He went to Wayne State University School of Medicine. Wayne State University School of Medicine is ranked 63/85 in Research/PrimaryCare. Jeffrey A. Zonder is a published doctor. He published 35 publications, including: 'Targeting Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Result...
- Targeting Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity.
- Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single agent activity in patients with relapsed multiple Myeloma.
- A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple Myeloma: SWOG S0434.
- Treatment outcomes in patients with relapsed and refractory multiple Myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.
- Evaluating the effects of lenalidomide induction therapy on peripheral stem Cells collection in patients undergoing autologous stem Cell transplant for multiple myeloma.
- A Phase I Dose-Escalation Trial of High-Dose Melphalan with Palifermin for Cytoprotection Followed by Autologous Stem Cell Transplantation for Patients with Multiple M...
- Secondary Primary Malignancies in Multiple Myeloma: An Old Nemesis Revisited.
- A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple Myeloma.
- Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple Myeloma: a randomized Southwest Oncology Group trial (S0232).
- The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple Myeloma patients with impaired renal function.
- Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untre...
- Thalidomide- and lenalidomide-associated thromboembolism among patients with Cancer.
- Update on practical aspects of the treatment of chronic myeloid Leukemia with imatinib mesylate.
- Thrombotic complications in patients with newly diagnosed multiple Myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis.
- Thrombotic complications of Myeloma therapy.
- The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous Leukemia with inadequate hematologic or cytogenetic ...
- Practical aspects of the treatment of chronic myelogenous Leukemia with imatinib mesylate.
- Chronic lymphocytic Leukemia presenting in association with aplastic anemia.
- Prevention of thalidomide- and lenalidomide-associated Thrombosis in myeloma.
- Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I...
- A phase II trial of bryostatin 1 in the treatment of metastatic colorectal Cancer.
- Chromosome aberrations in a series of 120 multiple Myeloma cases with abnormal karyotypes.
- Dermatological complications following initiation of lenalidomide in a patient with Chronic lymphocytic leukaemia.
- Treatment of relapsed Acute promyelocytic leukemia with gemtuzumab ozogamicin and all-trans retinoic acid.
- The role of vertebral augmentation in multiple Myeloma: International Myeloma Working Group Consensus Statement.
- Clinical development of novel proteasome inhibitors for Cancer treatment.
- The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid Leukemia with secondary chromosomal aberrations.
- Myonecrosis in sickle cell Anemia-overlooked and underdiagnosed.
- Positive pregnancy tests in a postmenopausal woman due to beta-human chorionic gonadotropin production by multiple Myeloma.
- Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with Cancer: a multicentre, rando...
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.
- Precursor T cell Acute lymphoblastic lymphoma presenting as bilateral facial nerve palsy.
- Plasma cell Leukemia presenting as organizing pneumonia refractory to high-dose steroid therapy.
Schools
Wayne State University School Of Medicine
University Rochester
Wayne State University
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
- Internal Medicine
Accepted Insurances
- Choice Plus POS II
- Amerigroup (Wellpoint)
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Blue Care Network PCP Focus Network
- Group Employees PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Cofinity PPO
- Commercial Insurance Company
- Coventry Health Care
- Preferred PPO
- Choice Care PPO
- Medicaid
- Medicare MCR
- Molina
- MultiPlan PPO
- PHCS Network PPO
- Priority PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Education
-
Wayne State University School of Medicine -
University of Rochester
Hospital
-
DMC - Detroit Receiving Hospital -
DMC Harper University Hospital
Drug Facts
| NPI NUMBER | 1205874377 | |
| NPPES Provider LastName | ZONDER | |
| NPPES Provider FirstName | JEFFREY | |
| NPPES Provider ZIPCode | 48201 | |
| NPPES Provider State | MI | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 949.0 | |
| Distinct Opioid Count | 5.0 | |
| Opioid Claim Count | 121.0 | |
| Percent Opioid Claims | 12.75 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1205874377 |
| Last Name Of The Provider | ZONDER |
| First Name Of The Provider | JEFFREY |
| View All |
Similar Doctors
|
|
Dr. Jan Rival, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shireen A. Brohi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gagandeep Cheema, MD |
|
|
Dr. Jacob L. Moe, DO |
|
|
Dr. Shoba J. Jonnalagadda, MD |
|
|
Dr. Bhamini Sudhir, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michelle L. Bonnett, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. George R. Dirani, MD |
|
|
Dr. Lakshminarayanan Nandagopal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Keith F. Killu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harkanwal Dhillon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Zeina A. Nahleh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bassim Kobrossy, MD |
|
|
Rashmi Kanagal Shamanna, MB |